Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA.

J Virol. 2015 Aug;89(16):8130-51. doi: 10.1128/JVI.01221-14. Epub 2015 May 27.

2.

Characterization of CD8+ T cell differentiation following SIVΔnef vaccination by transcription factor expression profiling.

Billingsley JM, Rajakumar PA, Connole MA, Salisch NC, Adnan S, Kuzmichev YV, Hong HS, Reeves RK, Kang HJ, Li W, Li Q, Haase AT, Johnson RP.

PLoS Pathog. 2015 Mar 13;11(3):e1004740. doi: 10.1371/journal.ppat.1004740. eCollection 2015 Mar. Erratum in: PLoS Pathog. 2015 Jun;11(6):e1004968.

3.

Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.

Kulkarni RR, Rasheed MA, Bhaumik SK, Ranjan P, Cao W, Davis C, Marisetti K, Thomas S, Gangappa S, Sambhara S, Murali-Krishna K.

J Virol. 2014 Dec;88(24):13990-4001. doi: 10.1128/JVI.02273-14. Epub 2014 Sep 24.

4.

A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.

Lai RP, Hock M, Radzimanowski J, Tonks P, Hulsik DL, Effantin G, Seilly DJ, Dreja H, Kliche A, Wagner R, Barnett SW, Tumba N, Morris L, LaBranche CC, Montefiori DC, Seaman MS, Heeney JL, Weissenhorn W.

J Biol Chem. 2014 Oct 24;289(43):29912-26. doi: 10.1074/jbc.M114.569566. Epub 2014 Aug 26.

5.

Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees.

Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, Hallengärd D, Currier JR, Wieczorek L, Hasselrot K, Earl PL, Polonis VR, Marovich MA, Robb ML, Sandström E, Wahren B, Biberfeld G.

AIDS Res Hum Retroviruses. 2014 Mar;30(3):299-311. doi: 10.1089/AID.2013.0149. Epub 2013 Nov 15.

6.

CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.

Francella N, Gwyn SE, Yi Y, Li B, Xiao P, Elliott ST, Ortiz AM, Hoxie JA, Paiardini M, Silvestri G, Derdeyn CA, Collman RG.

J Virol. 2013 Sep;87(17):9719-32. doi: 10.1128/JVI.01254-13. Epub 2013 Jul 3.

7.

Influence of mismatch of Env sequences on vaccine protection by live attenuated simian immunodeficiency virus.

Manrique J, Piatak M, Lauer W, Johnson W, Mansfield K, Lifson J, Desrosiers R.

J Virol. 2013 Jul;87(13):7246-54. doi: 10.1128/JVI.00798-13. Epub 2013 May 1.

8.

A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine.

Meng Q, Lin Y, Ma J, Ma Y, Zhao L, Li S, Yang K, Zhou J, Shen R, Zhang X, Shao Y.

Viral Immunol. 2012 Dec;25(6):477-84. doi: 10.1089/vim.2012.0014. Epub 2012 Nov 21.

9.

ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.

Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT.

PLoS Pathog. 2012;8(8):e1002890. doi: 10.1371/journal.ppat.1002890. Epub 2012 Aug 23.

10.

Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.

Lai RP, Seaman MS, Tonks P, Wegmann F, Seilly DJ, Frost SD, LaBranche CC, Montefiori DC, Dey AK, Srivastava IK, Sattentau Q, Barnett SW, Heeney JL.

PLoS One. 2012;7(4):e35083. doi: 10.1371/journal.pone.0035083. Epub 2012 Apr 11.

11.

Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb ML, Ngauy V, de Souza MS, Paris R, Ferrari G, Bailer RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Koup RA, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH.

N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.

12.

Depletion of CD4⁺ T cells abrogates post-peak decline of viremia in SIV-infected rhesus macaques.

Ortiz AM, Klatt NR, Li B, Yi Y, Tabb B, Hao XP, Sternberg L, Lawson B, Carnathan PM, Cramer EM, Engram JC, Little DM, Ryzhova E, Gonzalez-Scarano F, Paiardini M, Ansari AA, Ratcliffe S, Else JG, Brenchley JM, Collman RG, Estes JD, Derdeyn CA, Silvestri G.

J Clin Invest. 2011 Nov;121(11):4433-45. doi: 10.1172/JCI46023. Epub 2011 Oct 17.

13.

Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy.

Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, Taylor S, Pybus OG, Mäkitalo B, Walther-Jallow L, Spångberg M, Thorstensson R, Achour A, Fenyö EM, Stewart-Jones GB, Spetz AL.

PLoS Pathog. 2010 Sep 2;6(9):e1001084. doi: 10.1371/journal.ppat.1001084.

14.

Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.

Liu L, Wan Y, Wu L, Sun J, Li H, Li H, Ma L, Shao Y.

Retrovirology. 2010 Sep 1;7:71. doi: 10.1186/1742-4690-7-71.

15.

Characterization of SIV in the oral cavity and in vitro inhibition of SIV by rhesus macaque saliva.

Thomas JS, Lacour N, Kozlowski PA, Nelson S, Bagby GJ, Amedee AM.

AIDS Res Hum Retroviruses. 2010 Aug;26(8):901-11. doi: 10.1089/aid.2009.0235.

16.

Evidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population.

Kuhrt D, Faith SA, Leone A, Rohankedkar M, Sodora DL, Picker LJ, Cole KS.

J Virol. 2010 Mar;84(5):2466-76. doi: 10.1128/JVI.01966-09. Epub 2009 Dec 23.

17.

Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1.

Salisch NC, Kaufmann DE, Awad AS, Reeves RK, Tighe DP, Li Y, Piatak M Jr, Lifson JD, Evans DT, Pereyra F, Freeman GJ, Johnson RP.

J Immunol. 2010 Jan 1;184(1):476-87. doi: 10.4049/jimmunol.0902781. Epub 2009 Nov 30.

18.

An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Craigo JK, Barnes S, Zhang B, Cook SJ, Howe L, Issel CJ, Montelaro RC.

Retrovirology. 2009 Oct 20;6:95. doi: 10.1186/1742-4690-6-95.

19.

Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Vagenas P, Williams VG, Piatak M Jr, Bess JW Jr, Lifson JD, Blanchard JL, Gettie A, Robbiani M.

J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):433-42. doi: 10.1097/QAI.0b013e3181b880f3.

20.

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

Zhao J, Lai L, Amara RR, Montefiori DC, Villinger F, Chennareddi L, Wyatt LS, Moss B, Robinson HL.

J Virol. 2009 May;83(9):4102-11. doi: 10.1128/JVI.02173-08. Epub 2009 Feb 18.

Items per page

Supplemental Content

Write to the Help Desk